Comment
Alan J Thompson
10
Faculty of Brain Sciences, University College London, London WC1E 6BT, UK [email protected]
11
AJT has received fees and support for travel from medDay, Novartis, Biogen Idec, Eisai, Genzyme, IMANOVA, and OptumInsight; he has received honoraria and support for travel for invited lectures or chairing from Novartis, EXCEMED/ Serono Symposia, and Remedica. 1
2 3 4
5 6 7 8 9
Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 2014; 83: 1022–24. Hauser SL, Chan JR, Oksenberg JR. Multiple sclerosis: prospects and promise. Ann Neurol 2013; 74: 317–27. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology 2011; 77: 1246–52. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006; 77: 918–26. Lublin F, Reingold S, Cohen J, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278–86. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015; 14: 183–93. Sorbara CD, Wagner NE, Ladwig A, et al. Pervasive axonal transport deficits in multiple sclerosis models. Neuron 2014; 84: 1183–90. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat Rev Neurosci 2012; 13: 507–14. Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol 2015; 14: 208–23.
12 13
14 15
16
17
18 19
Novartis International. Novartis provides update on fingolimod phase III trial in primary progressive MS (PPMS). Dec 1, 2014. http://www.novartis. com/newsroom/media-releases/en/2014/1875463.shtml (accessed Dec 9, 2014). Palace J, Robertson N. Modifying disability in progressive multiple sclerosis. Lancet 2014; 383: 2189–91. Parliamentary debates (Hansard). House of Commons official report, Nov 7, 2014 (volume 587, number 58). Chataway J, Nicholas R, Todd S, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler 2011; 17: 81–88. Fox RJ. Biomarkers for MS: unpuzzling the progressive multiple sclerosis puzzle. Neurology 2014; 83: 1488–89. Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol 2015; 14: 194–207. Thompson AJ, Toosy A, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol 2010; 9: 1182–95. Jensen HB, Ravnborg M, Dalgas U, Stenager E. 4-aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2014; 7: 97–113. Feinstein A, Dalgas U. The benefits of exercise in progressive MS: some cautious optimism. Mult Scler 2014; 20: 269–70. Coetzee T, Zaratin P, Gleason TL. Overcoming barriers in progressive multiple sclerosis research. Lancet Neurol 2015; 14: 132–33.
Corrections Raman SV, Hor KN, Mazur W, et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2015; 14: 153–61—In this Article (published online Dec 30, 2014), the second sentence of the Study design and participants section of the Methods should have read “All enrolment and follow-up visits were completed between March 3, 2012, and July 1, 2014”. In the Procedures section of the Methods, paragraph two should have read “Left ventricular mass, volumes, and ejection fraction were measured with software (Argus, Siemens Healthcare, Erlangen, Germany)”... These corrections have been made to the online version as of Jan 12, 2015, and are correct in the print version.
www.thelancet.com/neurology Vol 14 February 2015
135
Alan J Thompson
10
Faculty of Brain Sciences, University College London, London WC1E 6BT, UK [email protected]
11
AJT has received fees and support for travel from medDay, Novartis, Biogen Idec, Eisai, Genzyme, IMANOVA, and OptumInsight; he has received honoraria and support for travel for invited lectures or chairing from Novartis, EXCEMED/ Serono Symposia, and Remedica. 1
2 3 4
5 6 7 8 9
Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology 2014; 83: 1022–24. Hauser SL, Chan JR, Oksenberg JR. Multiple sclerosis: prospects and promise. Ann Neurol 2013; 74: 317–27. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology 2011; 77: 1246–52. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006; 77: 918–26. Lublin F, Reingold S, Cohen J, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83: 278–86. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015; 14: 183–93. Sorbara CD, Wagner NE, Ladwig A, et al. Pervasive axonal transport deficits in multiple sclerosis models. Neuron 2014; 84: 1183–90. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat Rev Neurosci 2012; 13: 507–14. Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol 2015; 14: 208–23.
12 13
14 15
16
17
18 19
Novartis International. Novartis provides update on fingolimod phase III trial in primary progressive MS (PPMS). Dec 1, 2014. http://www.novartis. com/newsroom/media-releases/en/2014/1875463.shtml (accessed Dec 9, 2014). Palace J, Robertson N. Modifying disability in progressive multiple sclerosis. Lancet 2014; 383: 2189–91. Parliamentary debates (Hansard). House of Commons official report, Nov 7, 2014 (volume 587, number 58). Chataway J, Nicholas R, Todd S, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler 2011; 17: 81–88. Fox RJ. Biomarkers for MS: unpuzzling the progressive multiple sclerosis puzzle. Neurology 2014; 83: 1488–89. Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol 2015; 14: 194–207. Thompson AJ, Toosy A, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol 2010; 9: 1182–95. Jensen HB, Ravnborg M, Dalgas U, Stenager E. 4-aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2014; 7: 97–113. Feinstein A, Dalgas U. The benefits of exercise in progressive MS: some cautious optimism. Mult Scler 2014; 20: 269–70. Coetzee T, Zaratin P, Gleason TL. Overcoming barriers in progressive multiple sclerosis research. Lancet Neurol 2015; 14: 132–33.
Corrections Raman SV, Hor KN, Mazur W, et al. Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2015; 14: 153–61—In this Article (published online Dec 30, 2014), the second sentence of the Study design and participants section of the Methods should have read “All enrolment and follow-up visits were completed between March 3, 2012, and July 1, 2014”. In the Procedures section of the Methods, paragraph two should have read “Left ventricular mass, volumes, and ejection fraction were measured with software (Argus, Siemens Healthcare, Erlangen, Germany)”... These corrections have been made to the online version as of Jan 12, 2015, and are correct in the print version.
www.thelancet.com/neurology Vol 14 February 2015
135
